AdCMVhSSTr2

AdCMVhSSTr2 is a replication-deficient adenoviral vector (typically Serotype 5) designed to deliver and express the human somatostatin receptor type 2 (hSSTR2) gene under the control of the Cytomegalovirus (CMV) promoter. This gene therapy approach is primarily utilized to induce or enhance the expression of SSTR2 on the surface of target cells, such as tumor cells that lack sufficient endogenous receptor levels. By overexpressing SSTR2, the treated cells become susceptible to imaging and therapeutic targeting using radiolabeled somatostatin analogs, such as 68Ga-DOTATATE for PET imaging or 177Lu-DOTATATE for peptide receptor radionuclide therapy (PRRT). This theranostic strategy aims to expand the utility of SSTR2-targeted agents to a broader range of malignancies beyond neuroendocrine tumors, including ovarian and breast cancers. Clinical development has primarily focused on Phase 1 safety and feasibility studies.

Other names

Ad-CMV-hSSTR2Ad-CMV-hSSTR-2Ad-CMV-hSSTR 2Ad5-CMV-hSSTR2Ad-5-CMV-hSSTR2Ad 5-CMV-hSSTR2Adenovirus-CMV-hSSTR2Adenovirus-CMV-hSSTR-2Adenovirus-CMV-hSSTR 2